Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Zealand Pharma and sanofi-aventis extend lixisenatide licensing agreement

June 9, 2010

Merck & Co. discloses new FABP inhibitors

June 9, 2010

Preliminary phase III data reported on oral insulin spray

June 8, 2010

New FABP inhibitors presented

June 8, 2010

FDA advisory committee review of lorcaserin set for September

June 7, 2010

PregLem reports phase III data on Esmya in uterine fibroids

June 4, 2010

StronBone bone graft substitute shows efficacy in vivo

June 4, 2010

Banyu and Merck & Co. disclose new DGAT-1 inhibitors

June 4, 2010

FDA accepts Orexigen's Contrave NDA in obesity for filing

June 3, 2010

FDA grants orphan drug status to THPB in Niemann Pick type C disease

June 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...